For the Inventor, By the Inventor

Enter assignee name

Pharma Mar, S.a.

USPTO Granted Patents = 81

CIPO Patents = 52

EPO Patents = 33

Trademarks = 9

Forward Citations = 606

Loading Chart...

Loading Chart...

267 inventors (with patents filed for the assignee):

Ignacio Manzanares (21 out of 22 patents)

Carmen Cuevas (17 out of 18 patents)

Simon Munt (15 out of 15 patents)

4. Dolores Garcia Gravalos (15 out of 32 patents)

5. Pilar Gallego (13 out of 14 patents)

6. Andrés Francesch Solloso (10 out of 11 patents)

7. Kenneth L Rinehart (10 out of 46 patents)

8. Maria Del Carmen Cuevas Marchante (9 out of 11 patents)

9. María Del Carmen Cuevas Marchante (6 out of 6 patents)

10. Marta Perez (6 out of 6 patents)

11. Alberto Rodriguez (6 out of 6 patents)

12. Valentin Martinez Barrasa (5 out of 5 patents)

13. Anna M Lithgow-Bertelloni (5 out of 5 patents)

14. María Garranzo García-Ibarrola (4 out of 5 patents)

15. Cristina Mateo Urbano (4 out of 4 patents)

Core Competencies:

SCLC Treatment

Thrombocytopenia Management

Neutropenia Management

Antitumoral Compounds

Antibody Drug Conjugates

Ecteinascidin Compounds

Aplidine Derivatives

Cancer Treatment

Multiple Myeloma Treatments

Variolin Derivatives

Anticancer Steroidal Lactones

Synthetic Methods for Antitumor Agents

81 patents: Sort by Forward Citations

1. 12440490 - Method of treating SCLC and managing thrombocytopenia (2025-10-14),

2. 12433890 - Method of treating SCLC and managing neutropenia (2025-10-07),

3. 12384800 - Antitumoral compounds (2025-08-12),

4. 12324806 - Method of treating SCLC and managing hepatotoxicity (2025-06-10),

5. 12215100 - Anticancer compounds (2025-02-04),

6. 11713325 - Antitumoral compounds (2023-08-01),

7. 11590129 - Combination therapy with an antitumor alkaloid (2023-02-28),

8. 11339180 - Antitumoral compounds (2022-05-24),

9. 11332480 - Antitumoral compounds (2022-05-17),

10. 11224663 - Antibody drug conjugates (2022-01-18),

11. 10538535 - Antitumoral compounds (2020-01-21),

12. 9827257 - Antitumoral compounds (2017-11-28),

13. 9750759 - Antitumoral compounds (2017-09-05),

14. 9428524 - Synthetic process for the manufacture of ecteinascidin compounds (2016-08-30),

15. 9192568 - Formulations comprising jorumycin-, renieramycin-, safracin- or saframycin-related compounds for treating proliferative diseases (2015-11-24),

PharmaMar is a biopharmaceutical company that focuses on the discovery, development, and commercialization of innovative marine-derived anticancer drugs. With a strong commitment to research and development, PharmaMar aims to improve the lives of cancer patients worldwide through its cutting-edge therapies. The company operates globally, collaborating with leading medical institutions and organizations to advance the field of oncology. For more information about PharmaMar and its groundbreaking work, please visit their website.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 9 2025

81 Patents

#3 in Madrid

#10 in Spain

#8,983 in the World

Pharma Mar, S.a.

Forward Citations = 606

267 inventors:

Ignacio Manzanares (21 out of 22 patents)

Carmen Cuevas (17 out of 18 patents)

Simon Munt (15 out of 15 patents)

4. Dolores Garcia Gravalos (15 out of 32 patents)

5. Pilar Gallego (13 out of 14 patents)

Please report any incorrect information to support@idiyas.com

Loading…